COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01257594
Recruitment Status : Completed
First Posted : December 9, 2010
Last Update Posted : April 23, 2019
Genentech, Inc.
OSI Pharmaceuticals
Information provided by (Responsible Party):
Andrew B Lassman, MD, Columbia University

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : November 22, 2016
Actual Study Completion Date : December 31, 2018